HbA1c

HbA1c, or glycated hemoglobin, is a biomarker that reflects average blood glucose levels over the past 2 to 3 months and is crucial for diagnosing and managing diabetes. Several factors beyond diabetes can influence HbA1c levels, including age, ethnicity, and certain medical conditions such as anemia and kidney disease. Emerging biosensor technologies are improving the accuracy and accessibility of HbA1c measurements, with electrochemical and point-of-care devices showing promise in providing rapid and reliable results. Genetic variations also play a significant role in HbA1c levels, affecting both measurement accuracy and clinical interpretation.

HbA1c is often compared with other glycemic markers like fructosamine and glycated albumin to better detect dysglycemic conditions. These alternative markers can provide complementary information, especially in cases where HbA1c may be unreliable due to hemoglobinopathies or other factors affecting red blood cell lifespan. Despite these advancements, the interpretation of HbA1c remains complex and should be considered alongside clinical context and patient history.

The evidence base for HbA1c is robust but evolving, with ongoing research refining measurement techniques and understanding genetic influences.

Sources

• HbA1c and factors other than diabetes mellitus affecting it. (PMID:20848057)
• Emerging biosensor probes for glycated hemoglobin (HbA1c) detection. (PMID:38709399)
• HbA1c: how do we measure it and what does it mean? (PMID:19300091)
• Trends in Quantification of HbA1c Using Electrochemical and Point-of-Care Analyzers. (PMID:36850502)
• Genetics of HbA1c: a case study in clinical translation. (PMID:29522974)
• HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions. (PMID:26126638)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._